When Is Observation Appropriate?

  • Kisseng Hsieh
  • Peter C. Albertsen
Part of the Current Clinical Urology book series (CCU)


The natural history of prostate cancer encompasses a wide spectrum of clinical outcomes. In the absence of treatment, some patients experience a rapid progression to metastases and death, whereas others live with their disease for many years, ultimately succumbing to competing medical hazards. Only about 30% of the patients in the Veterans Administration Cooperative Urological Research Group (VACURG) studies of prostate cancer actually died from prostate cancer (1). In 2003, an estimated 220,900 American men will be diagnosed with prostate cancer and 28,900 will die from this disease (2). These statistics suggest that variable outcomes are as prevalent today as they were approx half a century ago.


Radical Prostatectomy Gleason Score Localize Prostate Cancer Compete Risk Analysis Hereditary Prostate Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Treatment and survival of patients with cancer of the prostate. The Veterans Administration Co-operative Urological Research Group. Surg Gynecol Obstet 1967; 124: 1011–1017.Google Scholar
  2. 2.
    Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003; 53: 5–26.PubMedCrossRefGoogle Scholar
  3. 3.
    Holmberg L, Bill-Axelson A, Helegsen F, et al. for the Scandinavian Prostatic Cancer Group Study Number 4. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002; 347: 781–789.PubMedCrossRefGoogle Scholar
  4. 4.
    Carter BS, Beaty TH, Steinberg GD, Childs B, Walsh PC. Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci USA 1992; 89: 3367–3371.PubMedCrossRefGoogle Scholar
  5. 5.
    Carter BS, Bova GS, Beaty TH, et al. Hereditary prostate cancer: epidemiologic and clinical features. J Urol 1993; 150: 797–802.PubMedGoogle Scholar
  6. 6.
    Narod SA, Dupont A, Cusan L, et al. The impact of family history on early detection of prostate cancer. Nat Med 1995; 1: 99–101.PubMedCrossRefGoogle Scholar
  7. 7.
    Cerhan JR, Parker AS, Putnam SD, et al. Family history and prostate cancer risk in a population-based cohort of Iowa men. Cancer Epidemiol Biomarkers Prev 1999; 8: 53–60.PubMedGoogle Scholar
  8. 8.
    Lesko SM, Rosenberg L, Shapiro S. Family history and prostate cancer risk. Am J Epidemiol 1996; 144: 1041–1047.PubMedCrossRefGoogle Scholar
  9. 9.
    Monroe KR, Yu MC, Kolonel LN, et al. Evidence of an X-linked or recessive genetic component to prostate cancer risk. Nat Med 1995; 1: 827–829.PubMedCrossRefGoogle Scholar
  10. 10.
    Schaid DJ, McDonnell SK, Blute ML, Thibodeau SN. Evidence for autosomal dominant inheritance of prostate cancer. Am J Hum Genet 1998; 62: 1425–1438.PubMedCrossRefGoogle Scholar
  11. 11.
    Matikainen MP, Schleutker J, Morsky P, Kallioniemi OP, Tammela TL. Detection of subclinical cancers by prostate-specific antigen screening in asymptomatic men from high-risk prostate cancer families. Clin Cancer Res 1999; 5: 1275–1279.PubMedGoogle Scholar
  12. 12.
    Gronberg H, Wiklund F, Damber JE. Age specific risks of familial prostate carcinoma: a basis for screening recommendations in high risk populations. Cancer 1999; 86: 477–483.PubMedCrossRefGoogle Scholar
  13. 13.
    Smith JR, Freije D, Carpten JD, et al. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 1996; 274: 1371–1374.PubMedCrossRefGoogle Scholar
  14. 14.
    Berthon P, Valeri A, Cohen-Akenine A, et al. Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2–43. Am J Hum Genet 1998; 62: 1416–1424.PubMedCrossRefGoogle Scholar
  15. 15.
    Xu J, Meyers D, Freije D, et al. Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat Genet 1998; 20: 175–179.PubMedCrossRefGoogle Scholar
  16. 16.
    Gibbs M, Stanford JL, McIndoe RA, et al. Evidence for a rare prostate cancer-susceptibility locus at chromosome 1p36. Am J Hum Genet 1999; 64: 776–787.PubMedCrossRefGoogle Scholar
  17. 17.
    Bauer JJ, Srivastava S, Connelly RR, et al. Significance of familial history of prostate cancer to traditional prognostic variables, genetic biomarkers, and recurrence after radical prostatectomy. Urology 1998; 51: 970–976.PubMedCrossRefGoogle Scholar
  18. 18.
    Berry R, Schroeder JJ, French AJ, et al. Evidence for a prostate cancer-susceptibility locus on chromosome 20. Am J Hum Genet 2000; 67: 82–91.PubMedCrossRefGoogle Scholar
  19. 19.
    Bratt O, Kristoffersson U, Lundgren R, Olsson H. Familial and hereditary prostate cancer in southern Sweden. A population-based case-control study. Eur J Cancer 1999; 35: 272–277.PubMedCrossRefGoogle Scholar
  20. 20.
    Bastacky SI, Wojno KJ, Walsh PC, Carmichael MJ, Epstein JI. Pathological features of hereditary prostate cancer. J Urol 1995; 153: 987–992.PubMedCrossRefGoogle Scholar
  21. 21.
    Bratt O, Damber JE, Emanuelsson M, Gronberg H. Hereditary prostate cancer: clinical characteristics and survival. J Urol 2002; 167: 2423–2426.PubMedCrossRefGoogle Scholar
  22. 22.
    Keetch DW, Humphrey PA, Smith DS, Stahl D, Catalona WJ. Clinical and pathological features of hereditary prostate cancer. J Urol 1996; 155: 1841–1843.PubMedCrossRefGoogle Scholar
  23. 23.
    Valeri A, Azzouzi R, Drelon E, et al. Early-onset hereditary prostate cancer is not associated with specific clinical and biological features. Prostate 2000; 45: 66–71.PubMedCrossRefGoogle Scholar
  24. 24.
    Gronberg H, Damber L, Tavelin B, Damber JE. No difference in survival between sporadic, familial and hereditary prostate cancer. Br J Urol 1998; 82: 564–567.PubMedCrossRefGoogle Scholar
  25. 25.
    Bova GS, Partin AW, Isaacs SD, et al. Biological aggressiveness of hereditary prostate cancer: longterm evaluation following radical prostatectomy. J Urol 1998; 160: 660–663.PubMedCrossRefGoogle Scholar
  26. 26.
    Hanus MC, Zagars GK, Pollack A. Familial prostate cancer: outcome following radiation therapy with or without adjuvant androgen ablation. Int J Radiat Oncol Biol Phys 1999; 43: 379–383.PubMedCrossRefGoogle Scholar
  27. 27.
    Hanlon AL, Hanks GE. Patterns of inheritance and outcome in patients treated with external beam radiation for prostate cancer. Urology 1998; 52: 735–738.PubMedCrossRefGoogle Scholar
  28. 28.
    Bratt O. Hereditary prostate cancer: clinical aspects. J Urol 2002; 168: 906–913.PubMedCrossRefGoogle Scholar
  29. 29.
    von Eschenbach A, Ho R, Murphy GP, Cunningham M, Lins N. American Cancer Society guideline for the early detection of prostate cancer: update 1997. CA Cancer J Clin 1997; 47: 261–264.CrossRefGoogle Scholar
  30. 30.
    Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002; 52: 23–47.PubMedCrossRefGoogle Scholar
  31. 31.
    Hsing AW, Tsao L, Devesa SS. International trends and patterns of prostate cancer incidence and mortality. Int J Cancer 2000; 85: 60–67.PubMedCrossRefGoogle Scholar
  32. 32.
    Grossfeld GD, Latini DM, Downs T, Lubeck DP, Mehta SS, Carroll PR. Is ethnicity an independent predictor of prostate cancer recurrence after radical prostatectomy? J Urol 2002; 168: 2510–2515.PubMedCrossRefGoogle Scholar
  33. 32a.
    Eastham JA, Kattan MW. Disease recurrence in black and white men undergoing radical prostatectomy for clinical stage T1–T2 prostate cancer. J Urol 2000; 163: 143–145.PubMedCrossRefGoogle Scholar
  34. 33.
    Moul JW, Douglas TH, McCarthy WF, McLeod DG. Black race is an adverse prognostic factor for prostate cancer recurrence following radical prostatectomy in an equal access health care setting. J Urol 1996; 155: 1667–1673.PubMedCrossRefGoogle Scholar
  35. 34.
    Schwartz KL, Severson RK, Gurney JG, Montie JE. Trends in the stage specific incidence of prostate carcinoma in the Detroit metropolitan area, 1973–1994. Cancer 1996; 78: 1260–1266.PubMedCrossRefGoogle Scholar
  36. 35.
    Pienta KJ, Demers R, Hoff M, Kau TY, Montie JE, Severson RK. Effect of age and race on the survival of men with prostate cancer in the Metropolitan Detroit tricounty area, 1973 to 1987. Urology 1995;45:93–101; discussion 101–102.Google Scholar
  37. 36.
    Shimizu H, Ross RK, Bernstein L, Yatani R, Henderson BE, Mack TM. Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. Br J Cancer 1991; 63: 963–966.PubMedCrossRefGoogle Scholar
  38. 37.
    Kolonel LN. Fat, meat, and prostate cancer. Epidemiol Rev 2001; 23: 72–81.CrossRefGoogle Scholar
  39. 38.
    Bruning PF, Bonfrer JM. Free fatty acid concentrations correlated with the available fraction of estradiol in human plasma. Cancer Res 1986; 46: 2606–2609.PubMedGoogle Scholar
  40. 39.
    Pusateri DJ, Roth WT, Ross JK, Shultz TD. Dietary and hormonal evaluation of men at different risks for prostate cancer: plasma and fecal hormone-nutrient interrelationships. Am J Clin Nutr 1990; 51: 371–377.PubMedGoogle Scholar
  41. 40.
    Kumar NB, Besterman-Dahan K. Nutrients in the chemoprevention of prostate cancer: current and future prospects. Cancer Control 1999; 6: 580–586.PubMedGoogle Scholar
  42. 41.
    Evans BA, Griffiths K, Morton MS. Inhibition of 5 alpha-reductase in genital skin fibroblasts and prostate tissue by dietary lignans and isoflavonoids. J Endocrinol 1995; 147: 295–302.PubMedCrossRefGoogle Scholar
  43. 42.
    Santibanez JF, Navarro A, Martinez J. Genistein inhibits proliferation and in vitro invasive potential of human prostatic cancer cell lines. Anticancer Res 1997; 17: 1199–1204.PubMedGoogle Scholar
  44. 43.
    Davis JN, Muqim N, Bhuiyan M, Kucuk O, Pienta KJ, Sarkar FH. Inhibition of prostate specific antigen expression by genistein in prostate cancer cells. Int J Oncol 2000; 16: 1091–1097.PubMedGoogle Scholar
  45. 44.
    Fotsis T, Pepper M, Adlercreutz H, et al. Genistein, a dietary-derived inhibitor of in vitro angiogenesis. Proc Natl Acad Sci USA 1993; 90: 2690–2694.PubMedCrossRefGoogle Scholar
  46. 45.
    Rosenberg Zand RS, Jenkins DJ, Brown TJ, Diamandis EP. Flavonoids can block PSA production by breast and prostate cancer cell lines. Clin Chim Acta 2002; 317: 17–26.CrossRefGoogle Scholar
  47. 46.
    Kim H, Peterson TG, Barnes S. Mechanisms of action of the soy isoflavone genistein: emerging role for its effects via transforming growth factor beta signaling pathways. Am J Clin Nutr 1998; 68 (6 suppl): 1418S–1425S.PubMedGoogle Scholar
  48. 47.
    Barnes RW. Survival with conservative therapy. JAMA 1969; 210: 331–332.PubMedCrossRefGoogle Scholar
  49. 48.
    Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J. Long-term survival among men with conservatively treated localized prostate cancer. JAMA 1995; 274: 626–631.PubMedCrossRefGoogle Scholar
  50. 49.
    Kaplan MH, Feinstein AR. The importance of classifying initial co-morbidity in evaluatin the outcome of diabetes mellitus. J Chron Dis 1974; 27: 387–404.PubMedCrossRefGoogle Scholar
  51. 50.
    Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373–383.PubMedCrossRefGoogle Scholar
  52. 51.
    Greenfield S, Apolone G, McNeil BJ, Cleary PD. The importance of co-existent disease in the occurrence of postoperative complications and one-year recovery in patients undergoing total hip replacement. Comorbidity and outcomes after hip replacement. Med Care 1993; 31: 141–154.PubMedCrossRefGoogle Scholar
  53. 52.
    Mellinger G, Gleason D, Bailar J. The histology and prognosis of prostatic cancer. J Urol 1967; 97: 331–337.PubMedGoogle Scholar
  54. 53.
    Weideranders R, Stuber RV, Mota C, O’Connell D, Haslam GJ. Prognostic value of grading prostatic carcinoma. J Urol 1963; 89: 881–888.Google Scholar
  55. 54.
    Gleason D. Histologic grading and clinical staging of prostatic carcinoma. In: Tannenbaum M, ed. Urologic Pathology: The Prostate. Lea and Febiger, Philadelphia, 1977, pp. 171–198.Google Scholar
  56. 55.
    McNeal JE, Bostwick DG, Kindrachuk RA, Redwine EA, Freiha FS, Stamey TA. Patterns of progression in prostate cancer. Lancet 1986; 1: 60–63.PubMedCrossRefGoogle Scholar
  57. 56.
    Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987; 317: 909–916.PubMedCrossRefGoogle Scholar
  58. 57.
    Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whittemore AS, Schmid HP. Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 1993; 71 (3 suppl): 933–938.PubMedCrossRefGoogle Scholar
  59. 58.
    Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993; 270: 948–954.PubMedCrossRefGoogle Scholar
  60. 59.
    Partin AW, Kattan MW, Subong EN, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997; 277: 1445–1451.PubMedCrossRefGoogle Scholar
  61. 60.
    Johansson JE, Adami HO, Andersson SO, Bergstrom R, Krusemo UB, Kraaz W. Natural history of localised prostatic cancer. A population-based study in 223 untreated patients. Lancet 1989; 1: 799–803.PubMedCrossRefGoogle Scholar
  62. 61.
    Johansson JE, Adami HO, Andersson SO, Bergstrom R, Holmberg L, Krusemo UB. High 10-year survival rate in patients with early, untreated prostatic cancer. JAMA 1992; 267: 2191–2196.PubMedCrossRefGoogle Scholar
  63. 62.
    Johansson JE, Holmberg L, Johansson S, Bergstrom R, Adami HO. Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA 1997; 277: 467–471.PubMedCrossRefGoogle Scholar
  64. 63.
    Chodak GW, Thisted RA, Gerber GS, et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med 1994; 330: 242–248.PubMedCrossRefGoogle Scholar
  65. 64.
    Jones GW. Prospective, conservative management of localized prostate cancer. Cancer 1992; 70 (1 suppl): 307–310.PubMedCrossRefGoogle Scholar
  66. 65.
    Whitmore WF Jr, Warner JA, Thompson IM Jr. Expectant management of localized prostatic cancer. Cancer 1991; 67: 1091–1096.PubMedCrossRefGoogle Scholar
  67. 66.
    Adolfsson J, Carstensen J, Lowhagen T. Deferred treatment in clinically localised prostatic carcinoma. Br J Urol 1992; 69: 183–187.PubMedCrossRefGoogle Scholar
  68. 67.
    Goodman CM, Busuttil A, Chisholm GD. Age, and size and grade of tumour predict prognosis in incidentally diagnosed carcinoma of the prostate. Br J Urol 1988; 62: 576–580.PubMedCrossRefGoogle Scholar
  69. 68.
    Moskovitz B, Nitecki S, Richter Levin D. Cancer of the prostate: is there a need for aggressive treatment? Urol Int 1987; 42: 49–52.PubMedCrossRefGoogle Scholar
  70. 69.
    Lu-Yao GL, Yao SL. Population-based study of long-term survival in patients with clinically localised prostate cancer. Lancet 1997; 349: 906–910.PubMedCrossRefGoogle Scholar
  71. 70.
    Albertsen PC, Hanley JA, Gleason DF, Barry MJ. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998; 280: 975–980.PubMedCrossRefGoogle Scholar
  72. 71.
    Black WC, Welch HG. Advances in diagnostic imaging and overestimations of disease prevalence and the benefits of therapy. N Engl J Med 1993; 328: 1237–1243.PubMedCrossRefGoogle Scholar
  73. 72.
    Thompson IM, Goodman PJ, Tangen CT, et al. The influence of Finasteride on the development of prostate cancer. N Engl J Med 2003; 349: 213–222.CrossRefGoogle Scholar
  74. 73.
    Lu-Yao GL, McLerran D, Wasson J, Wennberg JE. An assessment of radical prostatectomy. Time trends, geographic variation, and outcomes. The prostate patient outcomes research team. JAMA 1993; 269: 2633–2636.PubMedCrossRefGoogle Scholar
  75. 74.
    Carter HB, Pearson JD, Metter EJ, et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992; 267: 2215–2220.PubMedCrossRefGoogle Scholar
  76. 75.
    Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 1995; 273: 289–294.PubMedCrossRefGoogle Scholar
  77. 76.
    Gerber GS, Thisted RA, Scardino PT, et al. Results of radical prostatectomy in men with clinically localized prostate cancer. JAMA 1996; 276: 615–619.PubMedCrossRefGoogle Scholar
  78. 77.
    Lu-Yao GL, Potosky AL, Albertsen PC, Wasson JH, Barry MJ, Wennberg JE. Follow-up prostate cancer treatments after radical prostatectomy: a population-based study. J Natl Cancer Inst 1996; 88: 166–173.PubMedCrossRefGoogle Scholar
  79. 78.
    Sweat SD, Bergstralh EJ, Slezak J, Blute ML, Zincke H. Competing risk analysis after radical prostatectomy for clinically nonmetastatic prostate adenocarcinoma according to clinical Gleason score and patient age. J Urol 2002; 168: 525–529.PubMedCrossRefGoogle Scholar
  80. 79.
    Whitmore WF Jr. Proceedings: the natural history of prostatic cancer. Cancer 1973; 32: 1104–1112.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2004

Authors and Affiliations

  • Kisseng Hsieh
  • Peter C. Albertsen

There are no affiliations available

Personalised recommendations